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ABSTRACT
Objective: Increasing prevalence of carbapenem resistant Gram negative bacteria is a serious clinical and public health 
challenge. Bacteria resistant to all available antibiotics (Pan Drug Resistance) herald the onset of post antibiotics era. We 
hereby report clinical profile of 13 patients with pan drug resistant gram negative isolates.
Methods: Retrospective analysis of 13 patients with pan drug resistant gram negative isolates over the last 18 months 
was done by medical records review. Identification of the isolates and susceptibility testing was done using VITEK auto 
analyzer in concordance with the corresponding CLSI guidelines.
Results: Out of four patients with bacteremic isolates, three patients received colistin based combination therapy. 
Though two of these patients had microbiologic clearance, all the three died. Out of the 9 patients with non bacteremic 
isolates, 4 had infection and 5 had colonization. Three (out of four) were treated with combination therapy including 
colistin and one patient received colistin monotherapy. All four patients had microbiological clearance. Three patients 
had clinical cure and were discharged. One patient later developed bacteremia and died.
Conclusion: Infections, particularly blood stream with pan drug resistant organisms has a higher mortality. Urgent 
studies to reevaluate existing therapeutic options and research into new antibiotic molecules are the need of the hour. 
J Microbiol Infect Dis 2014; 4(3): 86-91
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Tam dirençli gram negative bakterilerin doğuşu: Hindistan’dan ilk vaka serisi
ÖZET
Amaç: Karbapenem dirençli Gram negatif bakterilerin sıklığının artması halk sağlığı ve klinik yaklaşım açısından ciddi 
bir problemdir. Mevcut bütün antibiyotiklere dirençli (tam dirençli) bakteriler antibiyotik sonrası dönemin başladığının 
habercisidir. Burada tam dirençli gram negatif suşlarla enfekte 13 hastanın profilini sunmaktayız. 
Yöntemler: son 18 ay içerisinde takip edilen tam dirençli gram negatif izolatlarla enfekte olan 13 hastanın kayıtları 
retrospektif olarak incelendi. Bakterilerin izolasyonu ve duyarlılıkları CLSI rehberine uygun olarak VITEK otomatik analiz 
cihazı ile yapıldı. 
Bulgular: Bakteriyemili hastalardan üçü kolistin içeren kombinasyon tedavisi aldı. Bu hastalardan ikisinde bakteri kan-
dan temizlenmesine rağmen üçü de öldü. Bakteriyemi olmayan dokuz hastadan dördü enfeksiyon beşi ise kolonizasyon 
olarak kabul edildi. Bu dört hastadan üçü kolistin içeren kombinasyonla ve biri de tek başına kolistin ile tedavi edildi. 
Bu dört hastada mikrobiyolojik olarak temizlenme sağlandı. Üç hasta klinik olarak iyileşti ve taburcu edildi. Bir hastada 
daha sonra bekteriyemi gelişti ve öldü. 
Sonuç: Özellikle tam dirençli bakterilerle olan kan dolaşımı enfeksiyonları yüksek mortaliteye sahiptir. Şu anda mevcut 
tedavilerin yeniden gözden geçirecek çalışmalara ve yeni antibiyotik moleküllerini araştırmaya acil olarak ihtiyaç vardır.
Anahtar kelimeler: Tam direnç, gram negatif bakteri enfeksiyonları, kolistinGhafur A, et al. PDR gram negative infections 87
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INTRODUCTION
The emergence and dissemination of carbapenem 
resistance among Gram-negative bacteria is a seri-
ous public health threat and treatment of patients 
infected by these bacteria poses therapeutic chal-
lenge. Non availability of newer treatment options 
in fact led to re-evaluation of colistin, a drug intro-
duced into the market half a century ago and then 
out of use due to its toxicity profile. Now, the long 
dreaded colistin resistance and hence pan drug re-
sistance scenario among gram negative organism 
has emerged, leaving very little options to treat pa-
tients infected by these bacteria.
There are plenty of laboratory studies on the 
prevalence of colistin resistance. As per a review 
published in 2007, percentage of polymixin resis-
tance in 11 invitro studies ranged from 1.4%-5% 
and pan drug resistance rate of 1.9%-3.3%.1 A 
2001 Spanish study reported a very high colistin 
rate of 13.1% in A. baumannii.2 A study from Kuwait 
reported 12% resistance among Acinetobacter iso-
lates.3 The SENTRY study by Gales et al, published 
in 2006, reported 1.3% polymixin resistance and 
0.08% pan drug resistance amongst Pseudomo-
nas and 2.1 and 0.3% respectively in Acinetobacter 
spp. Out of the 8188 Klebsiella isolates tested 1.8% 
were resistant to colistin.4
A study from North India (Taneja et al) analyzed 
224 isolates of A. baumannii. Of the total isolates, 
3.5% and 16% of the carbapenem resistant MDR 
strains were found to be pan-drug resistant (PDR) 
i.e., resistant to both tigecycline and colistin.5 Chand 
Wattal et al from a tertiary care hospital in North 
India showed that 8% of the pseudomonas was 
colistin resistant.6 There are no studies from India 
outlining both the clinical and microbiological char-
acteristics of pan drug resistant isolates. This data if 
available will be extremely useful from a clinical and 
public health view point. We hereby report clinical 
profile of 13 patients with pan drug resistant gram 
negative bacterial isolates from various sites.
Objective of the study
To elaborate on the clinical characteristics, manage-
ment and outcome of patients with culture positivity 
for PDR gram negatives isolates.
METHODS
Retrospective analysis of 13 patients with pan drug 
resistant gram negative isolates, identified over a 
period of one and a half years was done by medical 
records review, in a tertiary care oncology and stem 
cell transplant centre in India.
The isolates were tracked from the microbi-
ology laboratory. Susceptibility testing was per-
formed using VITEK2 compact. The isolates were 
tested against piperacillin-tazobactam, gentamicin, 
amikacin, netilmycin, ceftazidime, cefoperazone-
sulbactam, cefepime, cefepime/tazobactam, imi-
penem,  meropenem,  ciprofloxacin,  trimethoprim/
sulfamethoxazole and tigecycline. While clear cut 
CLSI guidelines on breakpoints are available for 
Enterobacteriaceae and Pseudomonas for to most 
antibiotics, there is no defined breakpoint for ce-
foperazone-sulbactam and cefepime/tazobactam. 
Breakpoints of cefoperazone and cefepime were 
applied for them respectively. Antibiotic discs for 
these drugs were obtained from Hi Media Lab In-
dia. Colistin susceptibility was done using VITEK 2 
compact for all isolates and for some isolates MIC 
was assessed by E test according to availability. 
Pseudomonas isolates were considered to be re-
sistant to colistin if the MIC is > 8 and Acinetobacter 
if MIC > 4.7 There is no available colistin breakpoint 
for Enterobacteriaceae as per CLSI guideline, so 
EUCAST breakpoints were followed (S ≤2; R>2).8
Acinetobacter baumannii,  Pseudomonas and 
Enterobacteriaceae were considered to be Pan 
drug resistant (PDR) if isolates were resistant to 
all classes of anti pseudomonal agents. In addition 
non-pseudomonal isolates were tested against tige-
cycline.1 Hospital identification numbers of patients 
who had a positive culture with Pan drug resistant 
gram negative bacteria, between January 2012 and 
May 2013, were collected from Microbiology labora-
tory and their medical records were tracked and an-
alyzed. Data for variables like age, sex, co morbidi-
ties, ICU stay, presence of indwelling devices and 
prior antibiotic exposure were looked into. APACHE 
score, Charlson’s co morbidity index and Pitt’s bac-
teremic score was also calculated. Outcome, in-
cluding 28 day mortality was analyzed. 
RESULTS
A total of thirteen patients with pan drug resistant 
(PDR or possible PDR) isolates were analyzed. 
Bacteremic and non bacteremic isolates were ana-
lyzed separately. Four patients had bacteremia with 
possible pan drug resistant gram negative organ-
isms. Nine possible PDR gram negative bacteria 
were isolated from sites other than blood. Four of 
them had infection due to the organism (two UTI, 
one SSTI and one pneumonia) and five were colo-Ghafur A, et al. PDR gram negative infections 88
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nized. The demographic, clinical and microbiologi-
cal profile is detailed in Table 1. Three out of four 
patients had carbapenem exposure and three had 
colistin exposure during the same admission. Three 
patients had an indwelling device at the time of bac-
teremia. Three patients were treated and one was 
not willing to continue treatment due to personal 
reasons. All the patients who were treated received 
combination therapy with colistin, carbapenem, ti-
gecycline. Two patients had microbiological clear-
ance while cultures were not repeated in the other 
two. Three of them expired and one could not be 
followed up.
Table 1.1. Clinical profile of patients with PDR bacteremia
Avg Age S9.S Prior hospitalisation 3 out of 4
Avg APACHE II score 14.75 Length of stay in lCU prior to 
colistin resistance 25.75
Avg Charlson’s comorbidity 
index (age adjusted)
4 Indwelling devices present in 3 out 4
Avg Pitt’s bacteremic index 3.75 Tool leucocyte count
1 neutropenic (200) & 3 non neutropenics 
(avg- 8433)
Diagnosis
3 Malignancy (1 
hematological, 1 
meningioma & 1 ca 
larynx) and 1 trauma
Treatment
3 treated (combination therapy) & 1 not 
treated (discharge against medical advice)
Prior positive culture in the 
same hospitalisation
3 out 4 had a 
carbapenemase 
producer
Antibiotics (No.Of days)
Patient 1. Colitin (5), meropenem (5), 
tigecycline (5) Teicoplanin (5)
Patient 2. Colistin (7), tigecycline (5)
Patient 3. Colistin (12), meropenem (9) 
tigecycline (12)
Exposure to carbapenem 
& colistin in the same 
admission
Carbapenem- 3 out of 
4 Colistin 2 out of 4
Microbiological clearance 2 cleared & 2 cultures not repeated
Source
1 lung, 1 gut 
translocation & unclear Outcome 3 expired and 1 not followed
Table 1.2. Clinical profile of patients with PDR (non-bacteremic)
Avg Age 55 Prior hospitalisation 8 out of 9
Avg APACHE II score of infected 
patients
18 Length of stay in ICU 
prior to colistin resistance
20.44
Avg Charlson’s comorbidity index 
(age adjusted) of infected cases
6
Indwelling devices 
present in
6 out of 9
Diagnosis 3 malignancy, Strauna, 1 
myesthenia gravis
Toed leucocyte count 
(infected patients)
11,112
Prior positive culture in the same 
hospitalization
5 out of 9 had a 
carbapenemase producer Treatment
3 Combination therapy & 1 
monotherapy
Exposure to carbapenem & colistin in 
the same admission
Carbapenem-5 Colistin-7 Antibiotics (No. of days)
Patient 1. Colistin (5), meropenem (5)
Patient 2. Colistin (12)
Patient 3. Colistin (9), cefepime (5), 
teicoplanin (13)
Patient 4, Colistin (14), doripenem 
(12), tigecycline (14), rifampicin (6)
Infection/Colonisation 4 infection & 5 colonisers Microbiological clearance 5 out of 9 repeated and cleared
Site (infection) 2 urine, 1 wound, 1 lung
Outcome of infected 
patients 3 stable & discharged and 1 diedGhafur A, et al. PDR gram negative infections 89
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Out of the nine patients with non bacteremic 
possible PDR isolates, four had infection and five 
were colonized (two patients had UTI, one had skin 
and soft tissue infection and one had pneumonia). 
Eight out of the nine patients with possible PDR col-
onization or infection had prior hospitalization. Five 
patients had prior carbapenem exposure and seven 
had colistin exposure. Three (out of four) were treat-
ed with combination therapy with colistin and one 
or more of the following agents (carbapenem, tige-
cycline, rifampicin, cefepime). One patient received 
monotherapy with colistin. All four patients had mi-
crobiological clearance. Three patients had clinical 
cure were discharged. One patient progressed to 
bacteremia and died (Table 2).
Microbiological data of PDR isolates
Three out of four isolates from blood were Klebsi-
ella pneumoniae and the other was Acinetobacter 
baumannii. Colistin MIC by E test was available 
for three of them. Out of the three urinary isolates 
two were Klebsiella pneumoniae and one was En-
terobacter. Both the isolates from the wound were 
Klebsiella pneumoniae.  Pseudomonas was the 
commonest amongst the respiratory isolates (three 
out of four). The other was Acinetobacter bauman-
nii. Colistin MIC by E test was available for four out 
of the nine isolates. 
DISCUSSION
Treatment of extremely drug resistant bacteria 
poses a serious challenge to patients and the treat-
ing physicians. Antibiotic development pipe line 
against Gram negative bacteria is nearly dry and no 
new antibiotic is expected at least for the next few 
years.9 Colistin is the drug of choice for treatment 
of patients having severe infections due to these 
bacteria. Colistin usage, in parts of the world with 
high prevalence of XDR Gram negative bacteria 
has resulted in reports of colistin resistant.10-12 As 
expected with any other antibiotic, increased usage 
of colistin results in increasing reports of colistin re-
sistance.13,14 Only a few clinical studies have been 
published outlining clinical characteristics and the 
outcome of patients with PDR isolates, mostly from 
Greece.1,10,15-18
It should be noted that some of the earlier re-
ports on PDR bacteria haven’t included colistin sus-
ceptibility and may not be pan drug resistant as per 
the new international expert proposal.19-21 According 
to this new nomenclature, all antibiotics of the sug-
gested groups should be tested before reporting as 
pan drug resistant, making many earlier reports of 
“PDR” to “possible PDR“. We did not test for fos-
fomycin and chloramphenicol sensitivity of our iso-
lates and so all our PDR isolates, by the new defini-
tion becomes possible PDR. Beno et al reported 9 
cases and Falagas et al published two series (7 and 
28 patients), Tsioutis et al. reported 21 patients with 
pan drug resistant gram negative bacteria.10,15-18
In our study 4 patients had bacteremia, 2 had 
UTI, one had pneumonia and one had SSTI. Three 
out of four patients with bacteremia and 8 out of 9 
patients with non-bacteremic isolates had prior hos-
pitalization, an important risk factor, pointed out in 
other series as well. 
There is limited evidence from two previous 
clinical studies that isolation of a PDR organism 
is often preceded by isolation of an organism sus-
ceptible only to colistin.15,16 In our study, three out 
of four patients with possible PDR bacteremia had 
prior infections with colistin sensitive, carbapenem 
resistant organism for which they received colistin, 
tigecycline and carbapenem. In patients with non 
bacteremia infections, three out of four patients had 
a positive culture with a carbapenem resistant or-
ganism. All the four had prior colistin exposure. Two 
out of four had carbapenem exposure. One patient 
was exposed to ciprofloxacin.
Three out of four patients with possible PDR 
bacteremia were treated and one didn’t continue 
treatment due to personal reasons. All the three 
received combination therapy with a colistin based 
regimen. One patient received colistin and merope-
nem, second patient received colistin, meropenem 
and tigecycline and the third patient received co-
listin, meropenem, tigecycline, teicoplanin and ri-
fampicin. Three out of four patients with non bac-
teremic infections received combination therapy. 
One patient received colistin and meropenem, one 
received colistin, cefepime-tazobactam and teico-
planin and the third one received colistin, doripen-
em, rifampicin and tigecycline. One patient received 
colistin monotherapy. Beno et al study did not pro-
vide details on antibiotic therapy used to treat PDR 
infections in their series.15 In a study by Falagas et 
al on PDR infections with Klebsiella and Pseudo-
monas patients were treated with colistin combined 
with carbapenem, BLBLI, quinolone, aminoglyco-
side and co-trimoxazole in varying combinations.16 
In another study by Falagas et al, the possible PDR 
patients were treated with different combination of 
antibiotics.10 In a study from Greece, nine (42.9%) 
patients received monotherapy for the treatment of 
the PDR infection; six patients received tigecycline, 
two patients received meropenem, and one patient Ghafur A, et al. PDR gram negative infections 91
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received colistin. Twelve (57.1%) patients were 
treated with a combination of antibiotics, which was 
mainly based on colistin plus meropenem or doxy-
cycline or rifampicin or ciprofloxacin.18
Cure rate in Beno et al study was 5 out of the 
9 and in Falagas et al study was 5 out of 7. In the 
Falagas et al study overall in-hospital mortality was 
41.7% and infection related mortality 33.3%.10,15 In 
the study by Tsioutis et al. 16 patients were cured 
and 5 died. Three out of ten patients treated with a 
colistin containing regimen died. All seven patients 
treated with tigecycline were cured and they were 
also found to have a shorter duration of stay after 
infection onset.18 In our 4 patients with bacteremia 3 
died, though repeat cultures were negative in two. 
One patient with bacteremia could not be followed 
up and so outcome is not known. However amongst 
the non bacteremic isolates 3 out of 4 were dis-
charged and 1 expired. Reported mortality in other 
studies was 50%-100% for patients with PDR Kleb-
siella and 20% for Pseudomonas. In our study all 
the 3 patients with PDR isolates in the blood were 
Klebsiella pneumoniae and carried a very high mor-
tality.15,16
CONCLUSION
Infection due to Pan drug resistant bacteria is a 
therapeutic challenge as this heralds the dawn of 
post antibiotic era with clinicians left with no antibi-
otic option. Our study is the first published one on 
the topic from India, providing clinical characteris-
tics of patients with possible PDR isolates. The data 
also highlights the need for laboratory and clinical 
studies on combination therapy in the treatment of 
PDR and XDR Gram negative bacterial infections. 
Prospective studies on the topic are required on an 
urgent basis. Findings of such trials can guide clini-
cians to choose the best therapeutic option. With 
high carbapenem resistance rates and increasing 
colistin usage in many tertiary care centers in India, 
clinicians and laboratories should look out for colis-
tin resistance through appropriate laboratory tests. 
Early detection of colistin resistance helps in initiat-
ing proper infection control measures to prevent the 
spread of these bacteria in health care institutions.
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